Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib. (PubMed, Mol Cancer Ther) - Jun 25, 2026 - "Emavusertib in combination with anti-PD-1 therapy results in improved tumor-infiltrating lymphocyte recruitment, decreased myeloid derived suppressor cell function, and upregulation of interferon γ signaling resulting in improved survival in aggressive mouse models of melanoma brain metastases. This work supports the development of combination strategies of emavusertib with immune checkpoint blockade in melanoma brain metastases."
Checkpoint inhibition • Journal • CNS Lymphoma • Hematological Malignancies • Lymphoma • Melanoma • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Solid Tumor • IFNG • IRAK4 • MYD88
|
|
Alisha Bhatia; Amanda Acevedo; Bently P Doonan; Changlin Yang; Christina A von Roemeling; Duane A Mitchell; Erica Matich; Gabriel W Jobin; Jeet A Patel; Savannah L Carpenter; Skye M Speakman; Tyler Elliott; Vincent Archibald; Vrunda Trivedi
|